Comirnaty

Overview

The mRNA COVID-19 vaccine (BNT162b2 / tozinameran) co-developed and commercialized with Pfizer — the first mRNA vaccine authorized for human use and the product that validated the platform at global scale.

Marketed globally as an updated seasonal COVID-19 vaccine; still BioNTech's primary revenue driver, though sales are declining as demand normalizes and are expected to fall further in 2026.

Key Specs